TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05699135

A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.”

The sponsor’s own words in the registry.

Life of this trial

202220232024Registered2022-12-15Started2023-03-09Stopped2023-06-30

Vital statistics

Status
Terminated
Sponsor
Pfizer
Sponsor type
Industry
Conditions
Urinary Bladder Neoplasms; Bladder Cancer; Bladder Tumors; Urothelial Carcinoma
Interventions
Avelumab first-line maintenance
Participants
150
Sites
1
Countries
Canada

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.